文献速递外周动脉疾病静脉血栓栓塞

下肢血运重建后利伐沙班联合阿司匹林预防静脉血栓栓塞的RESOLUTION试验设计

Venous Thromboembolism in Patients Receiving Rivaroxaban Plus Aspirin or Standard Treatment after Lower Limb Revascularization-Rationale and Design of the RESOLUTION Trial.
PubMed 文献 · Ann Vasc Surg · 2025-11-11

RESOLUTION试验为前瞻性随机开放标签对照研究,拟纳入100例下肢血运重建患者,1:1随机接受标准双联抗血小板治疗3个月后阿司匹林(对照)或利伐沙班2.5mg每日两次联合阿司匹林100mg每日一次(干预)。主要结局为术后30天内静脉血栓栓塞发生率,通过常规下肢静脉超声评估。

要点

  • 下肢血运重建后静脉血栓栓塞预防证据有限,本研究评估利伐沙班联合阿司匹林的疗效与安全性。
  • 主要结局为术后30天静脉血栓栓塞发生率,采用常规下肢静脉超声评估。
  • 次要结局包括出血并发症及因出血导致的再入院或再手术。

核心结论

  • 该试验旨在评估利伐沙班联合阿司匹林降低下肢血运重建后静脉血栓栓塞发生率的疗效与安全性。

研究设计与样本

  • 前瞻性、随机、开放标签、对照试验,拟纳入100例接受下肢血运重建的患者,按1:1随机分组。

关键数值与推荐

  • 对照组:标准双联抗血小板治疗3个月后阿司匹林;干预组:利伐沙班2.5mg每日两次联合阿司匹林100mg每日一次。
  • 主要结局:术后30天内静脉血栓栓塞发生率,通过常规下肢静脉超声评估,不论有无症状。
  • 次要结局:社会人口学特征、出血并发症、因出血导致的再入院或再手术。
  • 采用Caprini和IMPROVE出血风险评分对静脉血栓栓塞和出血风险进行分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is a major cause of perioperative morbidity and mortality, particularly in patients undergoing lower limb revascularization (LLR) for peripheral arterial disease. Despite the known risk, evidence supporting optimal postoperative VTE prophylaxis in this population remains limited. This study aims to evaluate the efficacy and safety of rivaroxaban combined with aspirin in reducing VTE incidence after LLR. STUDY DESIGN: This prospective, randomized, open-label, controlled trial will enroll 100 patients undergoing LLR, randomized 1:1 to receive either the standard dual antiplatelet therapy for 3 months followed by aspirin (control) or rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily (intervention). The primary outcome is the incidence of VTE within 30 days postoperatively, assessed through routine lower limb venous ultrasound, regardless of symptoms. Secondary outcomes include sociodemographic characterization, bleeding complications, and hospital readmission or reoperation due to bleeding. VTE and bleeding risks will be stratified using the Caprini and IMPROVE Bleeding Risk Scores. The trial is registered at www. CLINICALTRIALS: gov (NCT06873321). SUMMARY: This trial will provide high-quality evidence regarding the efficacy and safety of rivaroxaban plus aspirin for postoperative VTE prophylaxis after LLR. If successful, the findings may support rivaroxaban as an effective strategy for extended prophylaxis, enhancing postoperative outcomes while maintaining an acceptable safety profile.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. de Oliveira Buril G, Portugal MF, Neves S, et al. Venous Thromboembolism in Patients Receiving Rivaroxaban Plus Aspirin or Standard Treatment after Lower Limb Revascularization-Rationale and Design of the RESOLUTION Trial. Ann Vasc Surg. 2025. PMID: 41232756. doi:10.1016/j.avsg.2025.10.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。